Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective study
rwPFS and OS were consistent with clinical trials of 2L IO regimens. The few patients who received IO in 1L and 2L had favorable rwPFS and OS. Future research on sequential IO therapies in 1L and 2L aNSCLC is warranted.
Authors
- Danielle Gentile
- Lyudmila Bazhenova (ORCID: https://orcid.org/0000-0001-8764-4359)
- Beilei Cai (ORCID: https://orcid.org/0000-0002-2762-3908)
- Bruce A. Feinberg (ORCID: https://orcid.org/0000-0001-9267-9994)
- Jonathan Kish (ORCID: https://orcid.org/0000-0002-5343-7498)
Institutions
- Novartis (Switzerland) (CH)
- University of California San Diego (US)
- Cardinal Health (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1080/14796694.2025.2477975
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Novartis Pharmaceuticals Corporation